Your Health, We Care
Another NameLuciLenacap,来那帕韦纳
IndicationsIn combination with other antiretroviral drugs, it is indicated for the treatment of heavily treated adult HIV-1-infected patients with multidrug resistance whose current antiretroviral treatment regi
Reg No.03 L 1316/25
Inspection NO.647-25
As a long-acting treatment option for HIV-1 developed by Lucius Pharmaceuticals, lenaprevir offers sustained and stable viral suppression to drug-resistant patients with a twice-yearly dosing regimen, boasting notable advantages in long-term treatment convenience and medication adherence.
Here is a brief summary of the key information about lenacapavir sodium.
The main active ingredient is lenacapavir sodium, which belongs to the class of HIV-1 capsid inhibitors.
It is indicated for adult HIV-1-infected patients who have received multiple prior treatments and whose current treatment regimens have failed due to drug resistance or intolerance.
The medication includes two initial dosing regimens (oral administration combined with subcutaneous injection), followed by maintenance therapy with a subcutaneous injection every 6 months.
Generally, no dosage adjustment is required for elderly patients or those with hepatic or renal impairment. However, the safety and efficacy data for pediatric patients and patients with severe hepatic impairment remain insufficient.
Currently, there is no data available regarding drug overdose. In case of an overdose, symptomatic and supportive treatment should be administered.
Both tablets and injections should be stored at room temperature and protected from light. Injections should be used as soon as possible after preparation.
The drug has low oral bioavailability, is slowly absorbed after subcutaneous injection, and has a long half-life, enabling long-acting treatment effects.
FDA，2024.11
